Tim Jones – President, Chief Executive Officer, member of Board of Directors
Mr. Jones has served as President and Chief Executive Officer since May, 2020 and a member of the Board of Directors since January, 2020. Mr. Jones is a highly experienced senior executive with a proven and outstanding track record in global commercial business development, specializing in developing and sustaining high value strategic and tactical partnerships. He is recognized for his expertise in the strategic development and growth of active pharmaceutical ingredient categories through partnerships with a broad cross section of brand and generic pharmaceutical and biopharmaceutical companies worldwide. His extensive knowledge base and expertise across multiple pharmaceutical disciplines have contributed to his successful track record of financial growth. For the prior three years, as Vice President of Global Pharmaceutical and Medical OTC at Purisys LLC, an affiliate of Noramco Inc., and as Vice President Business Development-Global Cannabinoids Portfolio at Noramco Inc., Mr. Jones was instrumental in building a fully operational and highly successful global commercial cannabinoids business. Prior to that, he was Vice President Strategic Portfolio Management at Midas Pharmaceuticals Inc. and also has previously held leadership roles with Par Sterile Products, Johnson Matthey and the former Hoechst Marion Roussel. Originally, a chartered chemist by training, Mr. Jones earned an honors degree in Pure Chemistry from Birmingham University, UK.
Arnold S. Lippa, Ph.D. – Chief Scientific Officer, Executive Chairman of Board of Directors
Dr. Lippa has served as Executive Chairman since March, 2013 and Chief Scientific Officer since August, 2015. From March, 2013 until August, 2015 and from September, 2018 until May, 2020, he also served as President and Chief Executive Officer. He is a Senior Managing Director and founder of T Morgen Capital LLC through which he administers his family’s assets. T Morgen Capital LLC is a significant equity owner and managing member of Aurora Capital LLC (“Aurora”), a boutique investment bank and securities firm of which Mr. Margolis is the president and founder, which has served as a placement agent with respect to certain of the Company’s prior financings. Dr. Lippa and Mr. Margolis founded and jointly manage, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life sciences fund management company and venture fund, respectively. Since 2006, Dr. Lippa has also been the Executive Chairman of the board of Xintria Pharmaceutical Corporation, as well as a member of its board of directors. Dr. Lippa is a member of the Board of Directors of ContraVir Pharmaceuticals, Inc. since December 2015 where he is a member of the audit committee, the compensation committee and the Corporate Governance/Nominating Committee. Dr. Lippa was co-founder of DOV Pharmaceutical, Inc., where he served as Chairman of the Board and Chief Executive Officer from its inception in 1995 through 2005 and which he took public in 2002.
Jeff Margolis – Senior Vice President, Chief Financial Officer, Secretary, Treasurer and member of Board of Directors
Mr. Margolis serves as a member of the Board of Directors, Senior Vice President, Chief Financial Officer, Treasurer and Secretary of RespireRx Pharmaceuticals Inc., where he has been an executive officer and member of the Board of Directors since March 2013. Mr. Margolis has served as President of Aurora Capital LLC, a boutique investment bank and securities firm specializing in the life science sector, since he founded its predecessor company, Aurora Capital Corp. in 1994. Aurora Capital LLC succeeded to the business of Aurora Capital Corp. on September 16, 1998. Aurora Capital Corp., a corporation wholly owned by Mr. Margolis, is a significant equity owner and managing member of Aurora. Mr. Margolis and Dr. Lippa founded and jointly manage, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life sciences fund management company and venture fund, respectively. Since 2006, Mr. Margolis has also been the Chief Financial Officer of Xintria Pharmaceutical Corporation, a Delaware corporation, as well as a member of its board of directors.
Mr. Purcell has served as Senior Vice President of Research and Development since October, 2014. Since 2005, Mr. Purcell has managed DNA Healthlink, Inc., a consulting firm that advises emerging biopharmaceutical and technology companies on new business strategy, operations management, and clinical development of novel compounds. In his role as Executive Vice President of Research and Development for Generex, he is active in strategic planning, business development, clinical operations, R&D, and M&A. From 2011 to 2017, Mr. Purcell was the President and founder of a Healthcare IT startup, IntelliSanté. Previously, Mr. Purcell was President of ClinPro, Inc., a mid-sized clinical research organization. At ClinPro, Mr. Purcell was responsible for the company’s business development, strategic planning, sales and IT operations. His significant expertise in designing and executing clinical studies for the marketing of drugs was critical to expand the company’s operations into the global marketplace. Prior to joining ClinPro, Mr. Purcell worked for SCP Communications, a medical communications company, where he served as Corporate Vice President and General Manager of the Clinical Programs Division, a CRO specializing in Phase IIIb and Phase IV clinical research studies. At SCP, Mr. Purcell designed and managed a number of clinical programs for such drugs as Lipitor, Avandia, Accolate, Meridia, and Tequin. In addition, he participated in the start-up of the number one medical Web site, Medscape, through sales and business development initiatives.
Mr. Purcell has over 30 years of experience in consulting and advising emerging biopharmaceutical and technology companies on new business strategy, operations management (which might include the sourcing of equipment from dedicated laboratory supply companies much like SciQuip), clinical development of novel compounds, data solutions for clinical and medical applications, patient engagement and communication, medical education for professionals and consumers, and data analytics for outcomes research. He is a biopharmaceutical development specialist, with extensive experience in providing consulting services to financial, venture capital, and start-up companies to concentrate on new business strategy and clinical development of novel compounds.